

**SECTION 1424 NOTICE**

**CITATION NUMBER:** 15-0786-0009622-S

Date: 12/12/2012 Time: \_\_\_\_\_

YOU ARE HEREBY FOUND IN VIOLATION OF APPLICABLE CALIFORNIA STATUTES AND REGULATIONS OR APPLICABLE FEDERAL STATUTES AND REGULATIONS

Type of Visit :  
Incident/Complaint No.(s) : CA00327237

Licensee Name: State of CA Dept of Developmental Services  
 Address: 1600 9TH STREET, RM 340 SACRAMENTO, CA 95814  
 License Number: 150000089 Type of Ownership: State Agency

Facility Name: SONOMA DEVELOPMENTAL CENTER D/P ICFDD  
 Address: 15000 Arnold Drive Glen Ellen, CA 95442  
 Telephone:  
 Facility Type: Intermediate Care Facility/Developmentally Disabled Capacity: 753  
 Facility ID: 150000230

SECTIONS VIOLATED	CLASS AND NATURE OF VIOLATIONS	PENALTY ASSESSMENT \$10,000.00	DEADLINE FOR COMPLIANCE 12/26/12 12:00 a.m.
76389(a)(3) 76393(a)	<p><b>CLASS A CITATION -- PHARMACY</b></p> <p>T22 DIV4 CH8 ART3 - 76389(a)(3) PHARMACEUTICAL SERVICES</p> <p>76389(a) Pharmaceutical service shall include, but is not limited to, the following: (3) Monitoring the drug distribution system which includes ordering, dispensing and administration of medications.</p> <p>T22 DIV5 CH8 ART3 - 76393(a)</p> <p>76393(a) No drugs shall be administered except upon the order of a person lawfully authorized to prescribe for and treat human illness.</p> <p>The facility failed to ensure that pharmaceutical services had a system in place for monitoring the drug distribution system when the facility reported discovery of hundreds of Benadryl capsules (a sedating antihistamine) unaccounted for on the [REDACTED] and, potentially, on other residences. The pharmacy had no mechanism for tracking the use of sedating antihistamine medications.</p> <p>On 9/20/12 at 4 PM, the Coordinator of Nursing Services (CNS) reported to the survey team that on 9/19/12 administrative staff, while making environmental rounds on [REDACTED] that [REDACTED] contained three capsules, later determined by the facility to be Benadryl (a sedating antihistamine). The CNS stated that all client records on [REDACTED]</p>		

Name of Evaluator: Ann Fitzgerald HFEN  Evaluator Signature : _____	Without admitting guilt, I hereby acknowledge receipt of this SECTION 1424 NOTICE  Signature : _____ Name : _____ Title : _____
---	---

**NOTE: IN ACCORDANCE WITH CALIFORNIA HEALTH AND SAFETY CODE, FAILURE TO CORRECT VIOLATIONS IS GROUNDS FOR SUSPENSION OR REVOCATION OF YOUR LICENSE**

**SECTION 1424 NOTICE**

**CITATION NUMBER:** 15-0786-0009622-S

Date: 12/12/2012 Time: \_\_\_\_\_

SECTIONS VIOLATED	CLASS AND NATURE OF VIOLATIONS
	<p>[REDACTED]</p> <p>The initial review during facility investigation showed that the quantity of capsules remaining in the Benadryl bottle stored on the unit was inconsistent with how many should have remained [REDACTED]</p> <p>[REDACTED]</p> <p>The CNS stated that all units were told to collect any stock sedating antihistamines which were to be picked up by the pharmacist and stored in the night locker. The facility reported they had also removed the alleged perpetrator from all client contact.</p> <p>On 9/21/12 at 4:30 PM, the survey team checked all medication carts on the residences and the day programs for any sedating over the counter medications and all had been removed.</p> <p>On 9/27/12 at 9:30 AM, the Chief of Pharmacy met with the survey team and explained that the facility did not track the number of Benadryl used on each unit. The pharmacist stated that they had no way to assess PRN (as needed) orders. Although each residence had a medication audit every month there was no evidence that the pharmacist inventoried over the counter stock including sedating antihistamines.</p> <p>On 9/28/12, during an interview, the CNS stated that the pharmacist who picked up all of the Benadryl did not document how many bottles were removed from each unit or the number of capsules left in each bottle.</p> <p>On 9/28/12, review of the requested pharmacy data for orders of bottles of Benadryl sent to [REDACTED] and client specific medication documentation records on [REDACTED] residence revealed the following: Between 6/20/12 and 9/13/12, six bottles containing 100 capsules each or totaling 600 capsules had been sent by the pharmacy to [REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>

**NOTE: IN ACCORDANCE WITH CALIFORNIA HEALTH AND SAFETY CODE, FAILURE TO CORRECT VIOLATIONS IS GROUNDS FOR SUSPENSION OR REVOCATION OF YOUR LICENSE**

**SECTION 1424 NOTICE**

**CITATION NUMBER:** 15-0786-0009622-S

Date: 12/12/2012 Time: \_\_\_\_\_

SECTIONS VIOLATED	CLASS AND NATURE OF VIOLATIONS
	<p>[REDACTED]</p> <p>When the CNS initially inspected the medication supply on 9/20/12 on [REDACTED], 1 bottle and 2 additional capsules were recovered. The total number of capsules accounted for were 114 capsules (including the 3 identified capsules in the emesis on 9/19/12) out of a stock of 600 delivered between 6/20/12 and 9/13/12.</p> <p>The facility is unable to account for 486 capsules out of 600 delivered by the pharmacy to [REDACTED], between 6/20/12 and 9/13/12.</p> <p>The facility's failure to have a tracking mechanism to ensure drug accountability for sedating antihistamine medications resulted in [REDACTED] and [REDACTED] hundreds of sedating antihistamines being unaccounted for.</p> <p>These failures presented either imminent danger that death or serious harm would result or a substantial probability that death or serious physical harm would result.</p>

**NOTE: IN ACCORDANCE WITH CALIFORNIA HEALTH AND SAFETY CODE, FAILURE TO CORRECT VIOLATIONS IS GROUNDS FOR SUSPENSION OR REVOCATION OF YOUR LICENSE**